Prime Medicine is a biotechnology company committed to delivering a class of differentiated one-time curative genetic therapies, Prime Editors, to address a spectrum of diseases by deploying Prime Editing technology. Co.'s in-licensed Prime Editing technology has the ability to repair mutations. Prime Editors have two main components that act together to edit deoxyribonucleic acid (DNA): a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme, and a pegRNA, that targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The PRME stock yearly return is shown above.
The yearly return on the PRME stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the PRME annual return calculation with any dividends reinvested as applicable (on ex-dates).
|